Gene Editing and Genetic Lung Disease. Basic Research Meets Therapeutic Application

Area of Science:

• Pulmonary Medicine
• Genetics
• Biotechnology

Background:

• Congenital lung diseases like cystic fibrosis have extensive genetic understanding but limited treatment options.
• The lung's barrier function and direct environmental access make targeted gene delivery feasible.
• CRISPR/Cas9 gene-editing technology presents a potential solution for correcting disease-causing mutations.

Purpose of the Study:

• To explore the potential of CRISPR/Cas9 gene editing for treating monogenic lung diseases.
• To review strategies for efficient and safe gene editing in pulmonary applications.
• To assess the feasibility of CRISPR/Cas9 for both in vivo and ex vivo lung disease correction.

Main Methods:

• Review of CRISPR/Cas9 technology and its application in monogenic disease models.
• Discussion of intratracheal and intranasal delivery methods for gene therapy.
• Consideration of targeting pulmonary stem/progenitor cells for enhanced editing.
• Evaluation of strategies to minimize off-target effects and assess long-term outcomes.

Main Results:

• CRISPR/Cas9 has demonstrated proof of concept in repairing/inactivating mutations in animal models.
• Potential applications include in vivo gene correction and ex vivo editing of airway stem cells.
• Strategies for improving efficiency and safety are crucial for clinical translation.

Conclusions:

• CRISPR/Cas9-mediated gene editing holds significant promise for correcting monogenic respiratory diseases.
• Further advancements in efficiency, safety, and delivery are necessary for clinical application.
• This technology may offer a novel therapeutic avenue for currently untreatable lung conditions.